Relmada Therapeutics, Inc.

Product Candidates

Developing products for the treatment of central nervous system (CNS) diseases.

Product Pipeline

Candidate
(Regulatory Path)
Indication Development Stage
REL-1017
d-Methadone(New Molecular Entity)
Novel NMDA antagonist for the treatment of depression and neuropathic pain
Preclinical
Phase 1
Phase 2
Phase 3
Preclinical Phase 1 Phase 2 Phase 3
REL-1015
LevoCap ER(505(b)(2) regulatory path)
Extended release, abuse resistant form of broad spectrum opioid levorphanol
Preclinical
Phase 1
Phase 2
Phase 3
Preclinical Phase 1 Phase 2 Phase 3
REL-1028
BuTab(505(b)(2) regulatory path)
First traditional oral tablet form of buprenorphine
Preclinical
Phase 1
Phase 2
Phase 3
Preclinical Phase 1 Phase 2 Phase 3
REL-1021
MepiGel(505(b)(2) regulatory path)
Topical gel dosage form of local anesthetic mepivacaine
Preclinical
Phase 1
Phase 2
Phase 3
Preclinical Phase 1 Phase 2 Phase 3

Projected stage of development in 12-24 months

Our Drug Candidates

REL-1017 (d-Methadone)

Novel NMDA receptor antagonist being developed for the treatment of depression and neuropathic pain.

View REL-1017 (d-Methadone)

Our Drug Candidates

REL-1015 (LevoCap ER)

Extended release, abuse resistant form of broad spectrum opioid levorphanol for treatment of chronic pain when an opioid is needed.

View REL-1015 (LevoCap ER)

Our Drug Candidates

REL-1028 (BuTab)

Novel oral formulations of modified release buprenorphine being developed for both chronic pain and opioid dependence indications.

View REL-1028 (BuTab)

Our Drug Candidates

REL-1021 (MepiGel)

Topical gel dosage form of local anesthetic mepivacaine for treatment of postherpetic neuralgia (PHN) and HIV-associated neuropathy.

View REL-1021 (MepiGel)

Pain Treatment Market

Pain Market Characteristics

Pain Market Characteristics

  • Largest prescription drug market in the world - 334 million RXs in US in 2013
  • Affects 1.5 billion people worldwide
  • Most frequent reason for physician visits in the United States
  • Affects more Americans than diabetes, heart disease, and cancer combined
  • US annual economic cost of health care due to pain is in excess of $560 billion

An Unsatisfied Market

  • Better pain drugs are needed
  • Only 55% feel their pain is “under control”
  • Only 23% believe their pain medications are “very effective”
  • The unmet medical need allows new pain drugs to expand the market rather than interfere with existing products
  • Greater demand exists for new Extended Release (ER) products because of their limited availability in the market today
An Unsatisfied Market